- Home
- CRAN vs CCCC Comparison
CRAN vs CCCC Comparison
Compare CRAN & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRAN | CCCC |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.7M | 394.0M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRAN | CCCC |
|---|---|---|
| Price | $10.14 | $2.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 159.0K | ★ 2.8M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $9.13 | $1.69 |
| 52 Week High | $10.21 | $5.17 |
Technical Indicators
Market Signals| Indicator | CRAN | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 59.99 | 41.18 |
| Support Level | $10.13 | $2.47 |
| Resistance Level | N/A | $3.25 |
| Average True Range (ATR) | 0.01 | 0.25 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 84.62 | 20.79 |
Price Performance
Historical ComparisonAbout CRAN Crane Harbor Acquisition Corp. II Class A Ordinary Shares
Crane Harbor Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.